COVID-19 Associated Coagulopathy: Inflammation and Coagulation Linkage
Keywords:
COVID-19 associated coagulopathy (CAC), Vascular thrombosis, Cytokine storm, EndotheliopathyAbstract
The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection, which causes coronavirus disease (COVID-19), has become a worldwide pandemic since emerging in December 2019. The severity of the disease ranges from asymptomatic carriers to severe manifestations, such as acute respiratory distress syndrome (ARDS) and multiorgan failure. The proposed etiology for severe disease and death were micro- and macro-vascular thromboses, which are major components of COVID-19 associated coagulopathy (CAC). CAC is associated with cytokine storm, causing inflammation, endothelial injury, and subsequent thrombosis. Heparin is useful in this circumstance because of many proposed mechanisms. Multiple studies have reported the benefit of heparin in decreasing mortality in critically ill patients. However, the optimal dose and duration are yet to be determined.
Downloads
References
Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13.
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6).
Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. medRxiv. 2020;8(7):681-686.
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.
Jamil A, Jamil U, Dahal S, et al. Abstract 14827: Risk of Venous Thromboembolism in Hospitalized COVID-19 Patients Undergoing Thromboprophylaxis: Meta-analysis of Cohort Studies. Circulation. 2020;142(3):14827.
Boonyawat K, Chantrathammachart P, Numthavaj P, et al. Incidence of thromboem-bolism in patients with COVID-19: a systematic review and meta-analysis. Thrombosis Journal. 2020;18(1):34.
Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis. Thrombosis and haemostasis. 2021;121(1):76-85.
Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thrombosis research. 2020;191:148-150.
Clausen TM, Sandoval DR, Spliid CB, et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;183(4):1043-1057.
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637.
Gustafson D, Raju S, Wu R, et al. Overcoming Barriers. Arteriosclerosis, Thrombosis, and Vascular Biology. 2020;40(8):1818-1829.
Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine. 2020;59:102969.
Buijsers B, Yanginlar C, de Nooijer A, et al. Increased Plasma Heparanase Activity in COVID-19 Patients. Frontiers in Immunology. 2020;11. doi: 10.3389/fimmu.2020.575047.
de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14(4):597-600.
McBane RD, 2nd, Torres Roldan VD, Niven AS, et al. Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. Mayo Clinic proceedings. 2020;95(11):2467-2486.
Uaprasert N, Moonla C, Sosothikul D, Rojnuckarin P, Chiasakul T. Systemic Coagulopathy in Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2021;27:1-9. doi: 10.1177/1076029620987629.
Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020:1-4.
Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research. 2020;191:145-147.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(4):844-847.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulo-pathy. J Thromb Haemost. 2020;18(5):1094-1099.
Zheng R, Zhou J, Song B, et al. COVID-19-associated coagulopathy: thromboembo-lism prophylaxis and poor prognosis in ICU. Exp Hematol Oncol. 2021;10(1):6.
Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 1993;82(11):3253-3258.
Xie X, Rivier AS, Zakrzewicz A, et al. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem. 2000;275(44):34818-34825.
Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy. 2020.
Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19. Journal of Thrombosis and Haemostasis. 2020;1859-1865. doi: 10.1111/jth.14929.
Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(1):122-124.
Bhoopat L, Martynova A, Choi A, et al. The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19. Blood. 2020;136(1):38-39.
Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347-1350.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
